We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Proper Dosage of Ketamine in Intravenous Regional Anesthesia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by University Health Network, Toronto.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: September 22, 2005
Last Update Posted: October 11, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Health Network, Toronto
Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.

Condition Intervention
Pain. Drug: Different dosages of Ketamine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Study Start Date: January 2004
Estimated Study Completion Date: January 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age: 18-70
  2. Weight: 50-100 kg
  3. ASA: I, II, III
  4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

Exclusion Criteria:

  1. Contraindication to IVRA such as sickle cell disease.
  2. Any known hypersensitivity reaction to Ketamine.
  3. History of chronic pain or regular medication with analgesics.
  4. History of opioid dependence.
  5. Drug of alcohol abuse.
  6. Psychiatric disorder.
  7. Allergy to acetaminophen or codeine
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00221871

Contact: Colin McCartney, MD (416)603-5118 colin.mccartney@uhn.on.ca

Canada, Ontario
University Health Network Recruiting
Toronto, Ontario, Canada, M5T2S8
Contact: Filomena Valle-Leutri, BSc    (416)603-5800 ext 2016    filomena.valle-leutri@uhn.on.ca   
Principal Investigator: Colin McCartney, MD         
Sub-Investigator: Vincent Chan, MD         
Sub-Investigator: Philip Peng, MD         
Sub-Investigator: Paul Tumber, MD         
Sponsors and Collaborators
University Health Network, Toronto
Principal Investigator: Colin McCartney, MD University Health Network, Toronto
  More Information

ClinicalTrials.gov Identifier: NCT00221871     History of Changes
Other Study ID Numbers: UHN02-0233-A
First Submitted: September 20, 2005
First Posted: September 22, 2005
Last Update Posted: October 11, 2006
Last Verified: September 2005

Additional relevant MeSH terms:
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action